Legend Biotech Corporation ADR (LEGN)
NASDAQ: LEGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 19.20 +0.42%
LEGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.72B
- Forward P/E
- 18.21
- EPS (TTM)
- -$0.52
- Dividend yield
- None
- 52-week range
- 16.24 – 37.50
- Day range
- 18.58 – 19.24
- Volume / Avg
- 1.57M / 2.35M
- Beta
- —
- Shares outstanding
- 194.49M
52-week range
LEGN stock today
Legend Biotech (LEGN) closed at $19.12 on Oct 7, up 2.14% (+$0.40), versus the S&P 500's 0.22% decline. At this level, LEGN sits near the bottom of its 52-week range of $16.24 to $37.50: 49.0% below the high, set on Jun 3, 2026 and 17.7% above the low. LEGN is down 12.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 39.1%.
Legend Biotech has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Legend Biotech
Company profileLegend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Ingrid Zhang
- Headquarters
- Somerset, NJ
- Employees
- 3,200
- IPO year
- 2020
- Website
- legendbiotech.com
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$46.50+143.20%
- Strong buy 5
- Buy 3
- Hold 5
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
LEGN news
All LEGN newsLegend Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs LEGN |
| OGNOrganon & Co. | 13.79 | +0.36% | $3.62B | vs LEGN |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs LEGN |
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs LEGN |
| XENEXenon Pharmaceuticals Inc. | 36.41 | -0.44% | $3.53B | vs LEGN |
| TLXTelix Pharmaceuticals Limited ADR | 11.12 | +3.15% | $3.78B | vs LEGN |
| IDYAIDEAYA Biosciences Inc. | 36.26 | -1.01% | $3.50B | vs LEGN |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs LEGN |
Indexes, lists and sector
Legend Biotech stock FAQ
What is Legend Biotech's stock price today?
LEGN last traded at $19.12 as of Oct 7, 4:00 PM EDT, up 2.14% on the day. Prices are delayed at least 15 minutes.
Who is Legend Biotech's CEO?
Ms. Ingrid Zhang is the chief executive officer of Legend Biotech Corporation ADR, which has about 3,200 employees.
What is the LEGN 52-week high?
The 52-week high for LEGN is $37.50 and the 52-week low is $16.24. The stock is currently 49.0% below its high.